Molecular markers and targeted therapy with novel agents: Prospects in the treatment of non-small cell lung cancer

Lung Cancer

Volumn 38, Issue 1 SUPPL., 2002, Pages 43-49

  Rosell, Rafael ^a   Fossella, Frank ^b   Milas, Luka ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Molecular markers; Non small cell lung cancer; Targeted therapy

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING 1; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; MESSENGER RNA; MOLECULAR MARKER; NAVELBINE; PACLITAXEL; PLATINUM; PROTEIN; PROTEIN TYROSINE KINASE; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE; STATHMIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DNA ADDUCT; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; LUNG NON SMALL CELL CANCER; MICROTUBULE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; XENOGRAFT;

EID: 0036924381     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0169-5002(02)00171-x     Document Type: Article

References (48)

1. Schiller JH, Harrington D, Sander A et al. A randomized phase III trial of four chemotherapy regimens in advanced NSCLC, Proc Am Soc Clin Oncol 2000;19:abstract A-2.
2. Kelly K., Crowley J., Bunn P.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group Trial. J. Clin. Oncol. 19:2001;3210-3218.
3. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 357:2001;1478-1484.
4. Betticher D.C., Hsu Schmitz S.F., Gauthier Y., et al. Neoadjuvant chemotherapy with docetaxel (DOC, taxotere) and cisplatin (CIS) in patients (pts) with non-small cell lung cancer (NSCLC), stage IIIA, N2 is highly active with few toxicities. Proc. Am. Soc. Clin. Oncol. 18:1999;473a. (Abstract 1824).
5. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16:1998;309-316.
6. Dabholkar M., Vionnet J., Bostick-Bruton F., et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94:1994;703-708.
7. Lord R.V.N., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8:2002;2286-2291.
8. Cardenal F., Lopez-Cabrerizo M.P., Anton A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 17:1999;12-18.
9. Sandler A, Neumanitis J, Denham C et al. Phase III study of cisplatin with or without gemcitabine in patients with advanced NSCLC, Proc Am Soc Clin Oncol 1998;17 A-1774.
10. Crino L., Scagliotti G.V., Ricci S., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17:1999;3522-3530.
11. Alberola V., Camps C., Provencia M., et al. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): results of a Spanish lung cancer group phase III trial (GEPC/98-02). Proc. Am. Soc. Clin. Oncol. 20:2001;1229. (Abstract).
12. Rosell R., Taron M., O'Brate A. Predictive molecular markers in non-small cell lung cancer. Curr. Opin. Oncol. 13:2001;101-109.
13. Furuta T., Ueda T., Aune G., et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62:2002;4809-4902.
14. Vogel U., Dybdahl M., Frentz G., et al. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat. Res. 461:2000;197-210.
15. Vogel U., Moller P., Dragsted L., et al. Inter-individual variation, seasonal variation and close correlation of OGG1 and ERCC1 mRNA levels in full blood from healthy volunteers. Carcinogenesis. 23:2002;1505-1509.
16. Spitz M.R., Wu X., Wang Y., et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61:2001;1354-1357.
17. Cheng L., Spitz M.R., Hong W.K., Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis. 21:2000;1527-1530.
18. Takebayashi Y., Nakayama K., Kanzaki A., et al. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett. 174:2001;115-125.
19. 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis. 22:2001;1437-1445.
20. Rosell R., Monzo M., Novello S., et al. Genetic markers of individual chemotherapy response in non-small cell lung cancer (NSCLC): a pharmacogenomic interpretation of an Italian Lung Cancer Project randomized trial. Proc. Am. Soc. Clin. Oncol. 21:2002;1199. (Abstract).
21. Sarries C, Haura EB, Roig B et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer, Pharmacogenomics 2002;3:(in press).
22. Font A., Taron M., Rosell R., et al. UGT1A1 Genotyping correlates with toxicity and survival in non-small-cell lung cancer (NSCLC) patients treated with second-line CPT-11/docetaxel. Proc. Am. Soc. Clin. Oncol. 20:2001;1357. (Abstract).
23. Iwata T., Namikawa K., Honma M., et al. Increased expression of mRNAs for microtubule disassembly molecules during nerve regeneration. Mol. Brain Res. 102:2002;105-109.
24. Rosell R., Monzo M., O'Brate A., Tarón M. Translational oncogenomics: toward rational therapeutic decision-making. Curr. Opin. Oncol. 14:2002;171-179.
25. Song S., Xu X.-C. Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-β in immortalized esophageal epithelial cells and esophageal cancer cells. Biochem. Biophys. Res. Commun. 281:2001;872-877.
26. Herbst R.S., Khuri F.R., Fossella F.V., Glisson B.S., Kies M.S., Pisters K.M., Riddle J.R., Terry K.A., Lee: J.S. ZD (Iressa) in non-small cell lung cancer. Clin. Lung Cancer. 2001:1839;27-32.
27. Ge G, Wu J, Wang Y, Lin Q. Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase, Biochem Biophys Res Commun 2002;25;290:914-920.
28. Penuel E., Schaefer G., Akita R.W., Sliwkowski M.X. Structural requirements for ErbB2 transactivation. Semin. Oncol. 28:(6 Suppl. 18):2001;36-42.
29. Volm M., Mattern J., Koomagi R. Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors. Int. J. Oncol. 13:1998;975-979.
30. Veale D., Kerr N., Gibson G.J., Kelly P.J., Harris A.L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br. J. Cancer. 68:1993;162-165.
31. Ohsaki Y., Tanno S., Fujita Y., et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep. 7:2000;603-607.
32. Pavelic K., Banjac Z., Pavelic J., Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 13:1993;1133-1137.
33. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:(10 Suppl.):1993;2379-2385.
34. Rusch V., Klimstra D., Venkatraman E., et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3:1997;515-522.
35. Fontanini G., Vignati S., Boldrini L., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res. 3:1997;861-865.
36. Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7:2001;1204-1213.
37. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer. 8:2001;3-9.
38. Ciardiello F., Bianco R., Damiano V., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5:1999;909-916.
39. Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 20:2001;7. (Abstract).
40. Tortora G., Caputo R., Pomatico G., et al. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin. Cancer Res. 5:1999;875-881.
41. Mason K.A., Hunter N.R., Milas M., et al. Docetaxel enhances tumor radioreponse in vivo. Clin. Cancer Res. 3:1997;2431-2438.
42. Hainsworth J., Vokes E. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Semin. Oncol. 28:(Suppl. 2):2001;22-27.
43. Akimoto T., Hunter N., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 5:1999;2884-2890.
44. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6:2000;701-708.
45. Nasu S., Ang K.K., Fan Z., Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. 51:2001;474-477.
46. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.
47. Bonner J.A., Raisch K.P., Trummell H.Q., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. 18:(21 Suppl.):2000;47S-53S.
48. Nasu S, Hunter N, Mason KA et al. C225 antiepidermal growth factor receptor (EGFR) antibody enhances human tumor xenograft response to radiation (XRT) and docetaxel (DOC). In: Program and abstracts of the forth-eighth annual meeting of the Radiation Research Society, 2001. p. 169 (abstract P27-367).